1. Introduction {#sec1-pharmaceuticals-11-00057}
===============

The path to new drug discovery has always been a road full of twists and turns. De novo drug discovery in particular is an expensive, time-consuming, and high risk process. For instance, the total average cost of developing a new drug, as per an estimate, ranges from \$2 billion to \$3 billion and it takes at least 13--15 years to bring a drug to the market---starting from initial discovery to the approval stage \[[@B1-pharmaceuticals-11-00057]\]. Further, the process suffers from a high rate of attrition. About 10% of the drugs that enter into clinical trials get approved by regulatory agencies \[[@B2-pharmaceuticals-11-00057]\]. The remaining 90% of the drugs fail due to inefficacy or high toxicity due to the limited predictive value of preclinical studies \[[@B3-pharmaceuticals-11-00057]\]. Nearly 62% of the compounds fail in Phase II and approximately 45% attrition occurs in Phase III \[[@B4-pharmaceuticals-11-00057]\]. These attritions are due to insufficient R&D productivity in identifying the drug response on the target due to the limited availability of preclinical disease models which has raised concerns in the pharmaceutical industry \[[@B5-pharmaceuticals-11-00057]\]. Despite rapid technological advances and exponential increases in pharmaceutical R&D investments, the number of newly approved drugs continues to be the same \[[@B6-pharmaceuticals-11-00057]\]. To overcome these challenges and to potentially bypass this productivity gap, more and more companies are resorting to "drug repositioning" or "drug repurposing" (sometimes also referred to as drug reprofiling, drug retasking, or therapeutic switching) or simply identifying and developing new therapeutic uses for existing or abandoned pharmacotherapies \[[@B7-pharmaceuticals-11-00057]\]. The premise is that since most approved compounds have known bioavailability and safety profiles, proven formulation and manufacturing routes, and reasonably characterized pharmacology, repositioned drugs can enter clinical phases more rapidly and at a lower cost than novel compounds. Further, the 90% therapeutic development failure rate means there are many existing, partially developed therapeutic candidates that could be re-visited, explored further, and potentially repurposed for a new disease, common or rare. It is therefore not surprising that in recent years, of the new drugs that reach their first markets, repositioned drugs have taken up to a percentage of \~30%! For instance, of the 113 new drugs and biologics approved or launched in 2017, only seven were first-in-class agents (an approved and launched first drug with a novel mechanism of action) while 36 were repositioned drugs \[[@B8-pharmaceuticals-11-00057]\]. As per an estimate, this bypassing can potentially make a drug available for use in patients within 3--12 years with a total estimated cost of \$40--80 million \[[@B9-pharmaceuticals-11-00057],[@B10-pharmaceuticals-11-00057]\].

Most of the successful cases of drug repurposing have been serendipitous discoveries rather than systematic, hypothesis-driven outcomes. These include the accidental discovery of thalidomide as an agent for leprosy or the more notable example of sildenafil, an angina medication developed in 1989 subsequently marketed as Viagra^®^, a blockbuster drug to treat erectile dysfunction \[[@B12-pharmaceuticals-11-00057]\] (see [Table 1](#pharmaceuticals-11-00057-t001){ref-type="table"} for additional examples of drug repositioning). De novo drug therapies for more than 8000 orphan or rare diseases are impossible to develop with the current R&D costs, however, drug repositioning with its premise of discovering hidden connections or building connections between a drug and disease hold promise for orphan disease therapy \[[@B13-pharmaceuticals-11-00057]\]. Further, revisiting the approved drugs for identifying new indications helps the pharmaceutical companies to extend the patent life of drugs, through application to adjacent diseases and also helps the company to protect the IP against competitors \[[@B14-pharmaceuticals-11-00057]\].

In-silico methods like data-mining, machine learning, and network-based approaches, offer an unprecedented opportunity to predict all possible drug repositioning candidates using available diverse and heterogeneous data sources from genomics and biomedical domains \[[@B15-pharmaceuticals-11-00057]\]. Indeed, predictive models have been built using these methods exploiting existing data such as protein targets, chemical structure, or phenotypic information such as profiles of side-effect, gene expression, etc. While the advances in computational sciences bring the possibility of applying novel algorithms and approaches to systems biology data, these datasets themselves have triggered fundamental research on more complex problems \[[@B16-pharmaceuticals-11-00057]\]. As a result of this hybrid approach of utilizing computational methods and experimental screenings, various modalities of drug repositioning methods have emerged. Computational drug repositioning methods focus on shared characteristics between two drugs and depending on what kind of drug discovery (drug-based or disease-based) \[[@B17-pharmaceuticals-11-00057]\], the methods can be classified in to target-based, expression-based, knowledge-based, chemical structure-based, pathway-based and mechanism of action-based \[[@B18-pharmaceuticals-11-00057]\]. In this review article, we briefly outline the recent progress in computational methods and strategies applied on the drug-disease data for drug repositioning investigations.

2. Approaches {#sec2-pharmaceuticals-11-00057}
=============

In silico drug repurposing challenges that are drug-centric (i.e., discovering new indications for existing drugs) or disease-centric (i.e., identifying an effective drug as a potential treatment for disease) have the common challenge of either assessing the similarity or connections between drugs or between diseases \[[@B19-pharmaceuticals-11-00057]\]. Jin and Wong \[[@B18-pharmaceuticals-11-00057]\] reviewed a variety of approaches used as a basis for computational drug repurposing. These can be broadly categorized as knowledge-based and signature-based approaches.

2.1. Knowledge-Based Drug Repurposing {#sec2dot1-pharmaceuticals-11-00057}
-------------------------------------

This repurposing method utilizes the available information on drug such as drug-targets, chemical structures, adverse effects, pathways etc. and builds computational models to predict unknown mechanisms, targets or new bio-markers for diseases \[[@B20-pharmaceuticals-11-00057],[@B21-pharmaceuticals-11-00057],[@B22-pharmaceuticals-11-00057],[@B23-pharmaceuticals-11-00057],[@B24-pharmaceuticals-11-00057]\]. In pathway-based approach, signaling pathways, metabolic pathways and protein-interaction networks data are used to compute the similarity or connections between drug and disease. The processed omics data, for example, from human patients or animal models of disease are used to reconstruct disease-specific pathways that can serve as key targets for novel therapeutic discovery or for repositioned drugs \[[@B25-pharmaceuticals-11-00057],[@B26-pharmaceuticals-11-00057],[@B27-pharmaceuticals-11-00057],[@B28-pharmaceuticals-11-00057],[@B29-pharmaceuticals-11-00057],[@B30-pharmaceuticals-11-00057]\]. Target mechanism-based approaches on the other hand take into account known mechanism of action and target role : Here, the data available on signaling pathways, protein interactions and omics data are integrated to identify the potential mechanism of action (MoA) of drugs \[[@B31-pharmaceuticals-11-00057],[@B32-pharmaceuticals-11-00057],[@B33-pharmaceuticals-11-00057],[@B34-pharmaceuticals-11-00057]\]. This in turn can enable find better and even specific drug targets and also for discover of an alternate medication for any disease.

2.2. Signature-Based Drug Repurposing {#sec2dot2-pharmaceuticals-11-00057}
-------------------------------------

This method makes use of gene expression signatures by comparing drug gene expression profiles and disease gene expression profiles and is frequently referred to as 'signature reversion' method \[[@B35-pharmaceuticals-11-00057]\]. Gene expression based methods are effective in constructing a detailed map of connections between diseases and drug actions \[[@B36-pharmaceuticals-11-00057],[@B37-pharmaceuticals-11-00057],[@B38-pharmaceuticals-11-00057],[@B39-pharmaceuticals-11-00057],[@B40-pharmaceuticals-11-00057]\].

Connectivity Map (CMap) \[[@B83-pharmaceuticals-11-00057],[@B84-pharmaceuticals-11-00057]\], NCBI's Gene Expression (GEO) \[[@B75-pharmaceuticals-11-00057]\], and the relatively recent LINCS datasets \[[@B44-pharmaceuticals-11-00057]\] are also extensively explored in drug repositioning studies. Recent technical and technological advancements in molecular biology and exponential growth of biomedical data while presenting challenges have also opened up an array of opportunities to develop and apply novel and powerful computational approaches that can enable informed drug repositioning. The free availability of data repositories are further directing and catalyzing these efforts. In [Table 2](#pharmaceuticals-11-00057-t002){ref-type="table"} we present some of the widely used open source drug- and disease-centric and related databases. These include, for instance, databases that provide information on the known targets, mechanism of action, gene expression, clinical status, ADMET properties, signaling pathways and disease-centric database which has omics data (transcriptomic, proteomic, genetic characteristics of diseases).

2.3. In Silico Methods for Drug Repositioning {#sec2dot3-pharmaceuticals-11-00057}
---------------------------------------------

In the following sections, we present an overview of some of the in silico methods---current and emerging---used for facilitating drug repositioning candidate discovery.

### 2.3.1. Machine Learning {#sec2dot3dot1-pharmaceuticals-11-00057}

Any machine learning workflow typically comprises of 4 steps: data pre-processing, feature extraction, model fitting and evaluation \[[@B85-pharmaceuticals-11-00057]\]. PREDICT, is a similarity based machine learning framework, integrating drug-drug similarity (based on drug-protein interactions, sequence and gene-ontology) and disease-disease similarity (disease-phenotype and human phenotype ontology) where the authors have used them as features applying logistic regression to predict similar drugs for similar diseases and they achieved AUC = 0.9 in predicting drug indications \[[@B86-pharmaceuticals-11-00057]\]. SPACE, another similarity-based method predicts anatomical therapeutic chemical classification of drugs by integrating multiple data sources using Logistic Regression \[[@B87-pharmaceuticals-11-00057]\]. Likewise, several such similarity based methods have been reported for predicting novel drug indications \[[@B88-pharmaceuticals-11-00057],[@B89-pharmaceuticals-11-00057],[@B90-pharmaceuticals-11-00057]\].

Deep learning, a large class of machine learning-based models composed of multiple processing layers representing data with a high level of abstraction are now being explored computational biology field for a wide-variety of applications including drug discovery \[[@B91-pharmaceuticals-11-00057],[@B92-pharmaceuticals-11-00057]\]. The principal difference between conventional "shallow" learning (neural network with one or two hidden layers) and deep learning is that while the former does not deal with raw data and requires a feature extraction step to be performed before the learning process, the latter not only discovers intricate structure in large data sets but by using the backpropagation algorithm allows changing the internal parameters incrementally to compute the representation in each layer from the representation in the previous layer \[[@B92-pharmaceuticals-11-00057]\]. Deep learning-based approaches have dramatically improved the state-of-the-art in speech recognition, visual object recognition, object detection and are currently being explored in biomedical and genomic domains. Aliper and Plis, for example, used deep learning with gene expression data to learn drug therapeutic categories and found that deep neural networks surpassed SVM after 10 fold cross validation suggesting a working proof for applying deep learning for drug discovery and development \[[@B93-pharmaceuticals-11-00057]\]. Interestingly, Zhao and Cheong, compared deep neural networks (DNN) approach with SVM-based approach to predict psychiatric drug indications based on the expression profiles of drugs and reported that \[[@B37-pharmaceuticals-11-00057]\]. While more studies are needed to understand if DNN-based approaches indeed have the claimed benefits, there have been additional reports suggesting that deep learning-based approaches perform better than traditional machine learning algorithms in toxicity prediction by enabling multi-task learning \[[@B94-pharmaceuticals-11-00057],[@B95-pharmaceuticals-11-00057]\].

### 2.3.2. Network Models {#sec2dot3dot2-pharmaceuticals-11-00057}

Network-based approaches have been extensively exploited in computational drug repositioning for identifying novel drug targets, interactions, and indications \[[@B96-pharmaceuticals-11-00057]\]. Typically, in these models, the nodes in the networks represent either drug, disease, or gene products and edges represent the interactions or relationships between them. These networks are either knowledge-based or computationally inferred using multiple data resources and have various representations such as drug-drug, drug-target, drug-disease, disease-disease, disease-gene, disease-drug, protein-protein interactions, and transcriptional networks \[[@B97-pharmaceuticals-11-00057]\]. Cheng and Liu computed similarities---drug-based, target-based, and network-based---to predict drug-target interaction in a bi-partite network and found that network based inference method performed best with an average ROC AUC of 0.96 \[[@B21-pharmaceuticals-11-00057]\]. Similar homogenous or bipartite network models have been incorporated using phenotype data such as side-effect \[[@B98-pharmaceuticals-11-00057],[@B99-pharmaceuticals-11-00057],[@B100-pharmaceuticals-11-00057]\], transcriptional \[[@B101-pharmaceuticals-11-00057],[@B102-pharmaceuticals-11-00057],[@B103-pharmaceuticals-11-00057]\], drug-disease \[[@B104-pharmaceuticals-11-00057],[@B105-pharmaceuticals-11-00057]\] and signaling pathway data \[[@B25-pharmaceuticals-11-00057]\].

Integrating heterogeneous data also provides diverse information and has the potential to unveil hidden or unknown drug-disease relationships based on the guilt-by-association principle. Most of the similarity-based methods are either drug-centric or disease-centric networks, with relatively few approaches that built a drug-disease heterogeneous network using compendia of gene annotations and network clustering to identify drug repositioning candidates \[[@B105-pharmaceuticals-11-00057],[@B106-pharmaceuticals-11-00057]\]. Luo and Zhao, built a similar network-based framework using heterogeneous data through a network diffusion process and used the diffusion distributions to derive the prediction scores of drug-target interactions \[[@B107-pharmaceuticals-11-00057]\]. Recently, Himmelstein et al. integrated data from 29 public resources to identify dug repositioning candidates and predicted the probability of repositioning for 209,168 drug-disease pairs \[[@B108-pharmaceuticals-11-00057]\].

### 2.3.3. Mining Electronic Health Records for Drug Repurposing {#sec2dot3dot3-pharmaceuticals-11-00057}

Electronic health records (EHR) of the patients which provide medications details along with patient history can also be mined to identify drug repositioning candidates. Applying natural language processing on EHRs, for instance, reveals post-market, additional adverse drug events which are not found in clinical trials \[[@B109-pharmaceuticals-11-00057]\]. These side-effects information can be potentially used for drug-repositioning and validation \[[@B23-pharmaceuticals-11-00057]\]. Mining EHR records for example helped in identifying that metformin, a most commonly prescribed medication for type II diabetes, can also be repurposed for cancer treatment \[[@B110-pharmaceuticals-11-00057]\]. The relevance and accuracy of the model's prediction needs to be assessed in discovering a drug whose indications are unknown. The validity of novel drug prediction can be evaluated by comparing the predicted targets in ClinicalTrials.gov, PubMed abstracts or EHR records. The performance of the model can be evaluated by computing area under the ROC curve (AUC ROC) and Precision Recall (PR) curve. Sensitivity is a metric to measure the proportion of true positive identified correctly and Specificity is the proportion of negatives correctly identified as negatives. Due to the large unannotated drug-indication pairs as false positives, the sensitivity and specificity estimates are poor and creates substantial imbalance of true positives and true negatives. In a recent review, Brown and Patel suggest that using sensitivity-validation alone is ideal since it does not need the true negatives. The authors further suggest that investigators should test their model performance with cross-validation to prevent over-fitting and weak predictive performance \[[@B111-pharmaceuticals-11-00057]\].

2.4. Open Innovation---Crowd Sourcing {#sec2dot4-pharmaceuticals-11-00057}
-------------------------------------

Crowd sourcing is a collaborative approach of delegating tasks to the crowd where the variety of expertise available generates new insights or hypothesis with the available data. This paradigm has been taken advantage in a multitude areas from diverse domains including health care and genomics. The open source drug discovery process enables faster translation of research to results with a clear definition on specific problem, task decomposition and immediate feedback loop \[[@B112-pharmaceuticals-11-00057],[@B113-pharmaceuticals-11-00057],[@B114-pharmaceuticals-11-00057],[@B115-pharmaceuticals-11-00057]\]. Pharmaceutical companies, due to the limitations in R&D business model and man power often are focused on specific diseases which may or may not include rare and neglected diseases. Hence, few pharmaceutical and non-profit companies have used crowdsourcing platforms and embraced a wide-variety of innovative solutions \[[@B116-pharmaceuticals-11-00057],[@B117-pharmaceuticals-11-00057]\] directing towards discussing the scientific enigmas. Several open innovation platforms have been established in order to build industry-academia partnerships and to explore science and business opportunities with mutual benefit ([Table 3](#pharmaceuticals-11-00057-t003){ref-type="table"}).

### National Center for Advancing Translational Sciences (NCATS)---NIH-Academia-Industry Partnerships Initiative

The National Institutes of Health (NIH), as part of the new therapeutic uses program, launched (i) NCATS' NIH-Industry Partnerships initiative in 2012 to foster collaboration between pharmaceutical companies and the biomedical research community; and (ii) bench-to clinical repurposing initiative to test the utility of crowdsourcing efforts or computational approaches for drug repurposing.

The focus of the *match-making* NIH-industry partnerships projects is to match researchers with *open assets* from pharmaceutical assets to fuel and accelerate drug repurposing candidate discovery. Through this initiative, NCATS supports and advances research on a wide range of common and rare (including neglected) diseases. Current industry partners in this initiative include: AstraZeneca, AbbVie, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen Pharmaceuticals, MedImmune, Mereo BioPharma, Pfizer, and Sanofi. The participating companies make a number of partially developed assets available to academic researchers to crowdsource repurposing ideas. Projects using most of these assets can go directly into Phase II clinical trials, while some may require additional pre-clinical investigations or a Phase I clinical trial (e.g., testing in target populations to determine dosing, assess safety and tolerability).

Through the bench-to-clinic repurposing program, NCATS supports pre-clinical studies, clinical feasibility studies or proof-of-concept clinical trials to assess the utility of computational approaches or crowdsourcing efforts in discovering drug repurposing candidates. [Table 4](#pharmaceuticals-11-00057-t004){ref-type="table"} lists the new therapeutic uses projects funded by NIH-NCATS through these two programs (additional details can be found at <https://ncats.nih.gov/ntu/projects>).

2.5. Open Source Software {#sec2dot5-pharmaceuticals-11-00057}
-------------------------

The open source movement has created a substantial value in pursuing towards "*state-of-the-art*" research over the last decade with the help of reusable and generic software libraries for data processing \[[@B124-pharmaceuticals-11-00057],[@B125-pharmaceuticals-11-00057]\]. Jupyter Notebook for instance is the modern data analysis tool for reproducible computational research that supports open source languages like Python, Julia, C++, R and several other languages and provides rich features for interactive computing, visualization, and documentation \[[@B126-pharmaceuticals-11-00057]\]. Structured data tools like Scikit-learn \[[@B127-pharmaceuticals-11-00057]\], R-Programming, Orange \[[@B128-pharmaceuticals-11-00057]\] and Weka \[[@B129-pharmaceuticals-11-00057]\] are useful for mining, analysis, learning and statistical computing. For the high dimensional un-structured data such as images, text, or audio outputs, deep learning tools like TensorFlow \[[@B130-pharmaceuticals-11-00057]\], Keras \[[@B131-pharmaceuticals-11-00057]\], PyTorch \[[@B132-pharmaceuticals-11-00057]\], CNTK \[[@B133-pharmaceuticals-11-00057]\], and Matlab \[[@B134-pharmaceuticals-11-00057]\] that take advantage of multi-GPU accelerated training are increasingly used. Gephi \[[@B135-pharmaceuticals-11-00057]\] and Cytoscape \[[@B136-pharmaceuticals-11-00057]\] are other popular tools used primarily for bimolecular interaction networks, omics-data integration, clustering and visualization. In [Table 5](#pharmaceuticals-11-00057-t005){ref-type="table"}, we summarize few such used tools used in computational drug discovery and repositioning.

3. Discussion {#sec3-pharmaceuticals-11-00057}
=============

Drug repositioning acts as a viable strategy for a cost-effective de novo drug discovery. Although in silico methods have proven to be successful in addressing the problem of repurposing, some challenges continue to be addressed. One of the principal issues is the missing drug-disease indication data. Marking the missing indications as true negatives or ignoring them from training can potentially compromise the predictive power of the computational model for drug repurposing candidate discovery. Second, the lack of a true gold standard dataset for drug repositioning makes it difficult for in silico methods to evaluate results. As a result, common performance metrics such as sensitivity, specificity, and precision are used to assess the utility of computational drug repurposing algorithms. Third, existing computational methods tend to be predominantly one-sided (e.g., drug-centric or disease-centric). However, the integration of multi-omic data with similarity measures have been shown to have better predictive performance with identification of novel therapeutic compounds \[[@B105-pharmaceuticals-11-00057],[@B108-pharmaceuticals-11-00057]\].

The sea of biomedical information (see [Table 2](#pharmaceuticals-11-00057-t002){ref-type="table"}), in which small molecule and gene/protein structural, functional and process knowledge---both in normal and disease states---is embedded consists of unstructured free-text as in publications and structured or semi-structured relational databases. Transforming information from these silos into actionable knowledge is facilitated by establishing connectivity among the subsets taken from these multiple heterogeneous and diverse domains. For example, a *pharmacomodule* consisting of a group of genes, biological processes, pathways, phenotypes, small molecules (approved drugs or investigational compounds), and a group of drug-induced or related adverse events forms a meaningful multi-domain module when the interdependency among most of the pairs of subsets are supported by scientific evidence (literature or databases). These *pharmacomodules* can potentially take us closer to answering the *how* question about the underlying a hypothetical mechanism of action or phenomena. An informed answer to the *how* question holds the premise to generate better and informed drug repositioning hypotheses. Growing scientific evidence \[[@B7-pharmaceuticals-11-00057]\] suggests that any compound found to be safe in humans is likely to have multiple therapeutic uses. However, almost all successful drug reposition crossovers so far have been the result of either accidental occurrences or informed guesses. Given that this "back-to-basics" approach for repositioning is growing in popularity \[[@B8-pharmaceuticals-11-00057]\], there is an urgent need for more efficient and systematic computational approaches to first systematize the available genomic and pharmacological databases for representation and knowledge discovery and then use these databases and pattern discovery tools to identify the potential new uses for existing drugs. What is needed clearly is a paradigm shift in the approaches---genomic, biopharmacological, and computational---for a more informed systematic drug rediscovery ("systematic serendipity") taking into account all of the data resources. Originally coined by Eugene Garfield, "systematic serendipity" refers to the organized process of discovering previously unknown scientific relations using citation databases, leading to better possibilities for a collaboration of human serendipity with computer supported knowledge discovery \[[@B150-pharmaceuticals-11-00057]\].

The credibility of published research will improve the discoveries in science if the provided compendium has an evidence for the accuracy and reproducibility of the results. Reproducibility particularly is a major issue especially when scientific papers publish unexpected, positive results and other researchers or an independent research group is unable to replicate the same results even after using same or similar methods as reported by the original study \[[@B151-pharmaceuticals-11-00057],[@B152-pharmaceuticals-11-00057]\]. It has been estimated that the irreproducible research costs up to \$28 billion per year \[[@B153-pharmaceuticals-11-00057]\]! Providing the code and data used to obtain the claimed and reported results is always a better strategy than mere describing them in natural language in the paper and can be eventually an incremental step towards a better science \[[@B154-pharmaceuticals-11-00057],[@B155-pharmaceuticals-11-00057],[@B156-pharmaceuticals-11-00057]\]. The recent Findability, Accessibility, Interoperability, Reusability (FAIR) data principles go beyond the mere reuse of data by individuals but rather enhance the ability of machines to support and find and use the data automatically. These include any efforts that support discovery and reproducibility through good data management practices such as good data management, maintenance of the data flow, and sharing relevant tools or pipelines used in the research \[[@B157-pharmaceuticals-11-00057]\]. The recent Datasets2Tools project is in compliance with these principles and enables users to search for contributed canned analyses, datasets and tools \[[@B158-pharmaceuticals-11-00057]\]. Computational science research can be replicated effectively using tools like code version control software like Github \[[@B159-pharmaceuticals-11-00057]\] and transferable computational environments like Docker \[[@B160-pharmaceuticals-11-00057]\]. Over the past few years, the reproducibility issue is being taken seriously and many journals insist on providing code and data when submitting the paper.

In summary, emerging and advanced novel computational methods and crowdsourcing-based approaches that enable the joint analysis of genomic, biomedical and pharmacological data hold the premise to facilitate informed, efficient, and systematic drug repositioning. Whether this premise expedites drug development pipelines and how much of it translates into novel therapeutic discovery and impacts public health, especially catering to unmet needs (e.g., rare and neglected diseases), positively remains to be seen.
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pharmaceuticals-11-00057-t001_Table 1

###### 

Examples of repositioned drugs (adapted in part from \[[@B11-pharmaceuticals-11-00057]\], this list is neither extensive nor exhaustive).

  Drug            Original Indication            New Indication
  --------------- ------------------------------ ----------------------------------------------
  Allopurinol     Cancer                         Gout
  Amantadine      Influenza                      Parkinson's disease
  Amphotericin    Antifungal                     Leishmaniasis
  Arsenic         Syphilis                       Leukemia
  Aspirin         Inflammation, pain             Antiplatelet
  Atomexetine     Depressive disorder            ADHD
  Bimatoprost     Glaucoma                       Promoting eyelash growth
  Bromocriptine   Parkinson's disease            Diabetes mellitus
  Bupropion       Depression                     Smoking cessation
  Colchicine      Gout                           Recurrent pericarditis
  Colesevelam     Hyperlipidemia                 Type 2 diabetes mellitus
  Dapsone         Leprosy                        Malaria
  Disulfiram      Alcoholism                     Melanoma
  Doxepin         Depressive disorder            Antipruritic
  Eflornithine    Depression                     ADHD
  Finasteride     Benign prostatic hyperplasia   Male pattern baldness
  Gabapentin      Epilepsy                       Neuropathic pain
  Gemcitabine     Antiviral                      Cancer
  Lomitapide      Lipidemia                      Familial hypercholesterolemia
  Methotrexate    Cancer                         Psoriasis, rheumatoid arthritis
  Miltefosine     Cancer                         Visceral leishmaniasis
  Minoxidil       Hypertension                   Hair loss
  Naltrexone      Opioid addiction               Alcohol withdrawal
  Naproxen        Inflammation, pain             Alzheimer's disease
  Nortriptyline   Depression                     Neuropathic pain
  Premetrexed     Mesothelioma                   Lung cancer
  Propranolol     Hypertension                   Migraine prophylaxis
  Raloxifene      Contraceptive                  Osteoporosis
  Sildenafil      Angina                         Erectile dysfunction; pulmonary hypertension
  Thalidomide     Morning sickness               Leprosy; multiple myeloma
  Tretinoin       Acne                           Leukemia
  Zidovudine      Cancer                         HIV/AIDS
  Zileuton        Asthma                         Acne

pharmaceuticals-11-00057-t002_Table 2

###### 

Drug and Disease Centric Database Resources.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Database                                        Type               Description                                                                                                                                                                                                                                                                                                                                      URL                                                           Ref.
  ----------------------------------------------- ------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------- -------------------------------------
  ADReCS                                          Drug               System Toxicology and in silico drug safety evaluation. Contains 137,619 Drug-ADR pairs                                                                                                                                                                                                                                                          <http://bioinf.xmu.edu.cn/ADReCS/>                            \[[@B41-pharmaceuticals-11-00057]\]

  ChEMBL                                          Drug               Database of bioactive drug-like small molecules and abstracted bioactivities                                                                                                                                                                                                                                                                     <https://www.ebi.ac.uk/chembl>                                \[[@B42-pharmaceuticals-11-00057]\]

  ChemSpider                                      Drug               Database of 64 million chemical structures                                                                                                                                                                                                                                                                                                       <http://www.chemspider.com/>                                  \[[@B43-pharmaceuticals-11-00057]\]

  Clue (L1000 Platform)                           Drug               Dataset of transcriptional responses of human cells to chemical and genetic perturbation. 1.2 Million L1000 profiles and tools for their analysis.                                                                                                                                                                                               <https://clue.io/>                                            \[[@B44-pharmaceuticals-11-00057]\]

  Comparative Toxicogenomics Database             Drug               Associations of Drug-Gene, Gene-Disease, Drug-Disease and gene-gene                                                                                                                                                                                                                                                                              <http://ctdbase.org/>                                         \[[@B45-pharmaceuticals-11-00057]\]

  DailyMED                                        Drug               Catalogue of drug listings/drug label information                                                                                                                                                                                                                                                                                                <https://dailymed.nlm.nih.gov/dailymed/>                      \[[@B46-pharmaceuticals-11-00057]\]

  DGIdb                                           Drug               Drug-gene annotations, interactions and potential drug ability database                                                                                                                                                                                                                                                                          <http://dgidb.org/>                                           \[[@B47-pharmaceuticals-11-00057]\]

  DrugBank                                        Drug               Contains 11,000 drug entries and each entry contains more than 200 data fields of chemical information and drug targets.                                                                                                                                                                                                                         <https://www.drugbank.ca/>                                    \[[@B48-pharmaceuticals-11-00057]\]

  DrugCentral                                     Drug               Information on active ingredients chemical entities, pharmaceutical products, drug mode of action, indications, pharmacologic action                                                                                                                                                                                                             <http://drugcentral.org/>                                     \[[@B49-pharmaceuticals-11-00057]\]

  e-Drug3D                                        Drug               e-Drug3D offers a facility to explore FDA approved drugs and active metabolites                                                                                                                                                                                                                                                                  <http://chemoinfo.ipmc.cnrs.fr/MOLDB/index.html>              \[[@B50-pharmaceuticals-11-00057]\]

  Genomics of Drug Sensitivity in Cancer (GDSC)   Drug               Screenings of \>1000 genetically characterized human cancer cell lines with a wide range of anti-cancer therapeutics                                                                                                                                                                                                                             <http://www.cancerrxgene.org/>                                \[[@B51-pharmaceuticals-11-00057]\]

  Inxight Drugs                                   Drug               A comprehensive portal for drug development information from NCATS                                                                                                                                                                                                                                                                               <https://drugs.ncats.io/ginas/app>                            

  Open Targets Platform                           Drug               comprehensive and robust data integration for access to and visualization of potential drug targets associated with disease                                                                                                                                                                                                                      <https://www.targetvalidation.org>                            \[[@B52-pharmaceuticals-11-00057]\]

  PharmGKB                                        Drug               Curated dataset of genetic variation on drug response                                                                                                                                                                                                                                                                                            <https://www.pharmgkb.org/>                                   \[[@B53-pharmaceuticals-11-00057]\]

  pkCSM                                           Drug               Small-molecule pharmacokinetic (ADMET) properties prediction using SMILE data                                                                                                                                                                                                                                                                    <http://biosig.unimelb.edu.au/pkcsm/prediction>               \[[@B54-pharmaceuticals-11-00057]\]

  Project Achilles                                Drug               A genome-wide catalog of tumor dependencies, to identify vulnerabilities associated with genetic and epigenetic alterations                                                                                                                                                                                                                      <https://portals.broadinstitute.org/achilles>                 \[[@B55-pharmaceuticals-11-00057]\]

  Promiscuous                                     Drug               Database contains three different types of entities: drugs, proteins and side-effects as well as relations between them                                                                                                                                                                                                                          <http://bioinformatics.charite.de/promiscuous/>               \[[@B56-pharmaceuticals-11-00057]\]

  PubChem                                         Drug               PubChem contains more than 90 million compounds chemical information along with their bio activities, gene and protein targets                                                                                                                                                                                                                   <http://pubchem.ncbi.nlm.nih.gov/>                            \[[@B57-pharmaceuticals-11-00057]\]

  SIDER                                           Drug               Information on marketed medicines and their recorded adverse drug reactions                                                                                                                                                                                                                                                                      <http://sideeffects.embl.de/>                                 \[[@B58-pharmaceuticals-11-00057]\]

  STITCH                                          Drug               68,000 chemicals, interactions and over 1.5 million proteins in 373 species                                                                                                                                                                                                                                                                      <http://stitch.embl.de/>                                      \[[@B59-pharmaceuticals-11-00057]\]

  SuperPred                                       Drug               A prediction webserver for ATC code and target prediction of compounds                                                                                                                                                                                                                                                                           <http://prediction.charite.de/>                               \[[@B60-pharmaceuticals-11-00057]\]

  Therapeutic Target Database (TTD)               Drug               Dataset of known and explored therapeutic protein and nucleic acid targets, the targeted disease, pathway information and the corresponding drugs directed at each of these target                                                                                                                                                               <http://bidd.nus.edu.sg/group/cjttd/>                         \[[@B61-pharmaceuticals-11-00057]\]

  Toxin and Toxin-Target Database (T3DB)          Drug               A database of 3673 toxins described by 41,733 synonyms, including pollutants, pesticides, drugs, and food toxins, which are linked to 2087 corresponding toxin target records                                                                                                                                                                    <http://www.t3db.ca/>                                         \[[@B62-pharmaceuticals-11-00057]\]

  Human Protein Atlas                             Disease and Drug   Consists of three separate parts; the Tissue Atlas showing the distribution of the proteins across all major tissues and organs in the human body, the Cell Atlas showing the subcellular localization of proteins in single cells, and finally the Pathology Atlas showing the impact of protein levels for survival of patients with cancer.   <https://www.proteinatlas.org/>                               \[[@B63-pharmaceuticals-11-00057]\]

  KEGG Medicus                                    Disease and Drug   Collection of databases dealing with genomes, biological pathways, diseases, drugs, and chemical substances                                                                                                                                                                                                                                      <http://www.genome.jp/kegg/disease/>\                         \[[@B64-pharmaceuticals-11-00057]\]
                                                                                                                                                                                                                                                                                                                                                                                                                      <http://www.kegg.jp/>\                                        
                                                                                                                                                                                                                                                                                                                                                                                                                      <http://www.genome.jp/kegg/drug/>                             

  PsychEncode                                     Disease                                                                                                                                                                                                                                                                                                                                                             <https://www.synapse.org//#!Synapse:syn4921369/wiki/235539>   \[[@B65-pharmaceuticals-11-00057]\]

  Allen Brain Atlas                               Disease            Gene expression maps for mouse and human brain                                                                                                                                                                                                                                                                                                   <http://www.brain-map.org/>                                   \[[@B66-pharmaceuticals-11-00057]\]

  ArrayExpress                                    Disease            Micro array gene expression data at EBI                                                                                                                                                                                                                                                                                                          <https://www.ebi.ac.uk/arrayexpress>                          \[[@B67-pharmaceuticals-11-00057]\]

  CCLE                                            Disease            Database of mRNA expression and mutation data over 1100 cancer cell lines                                                                                                                                                                                                                                                                        <https://portals.broadinstitute.org/ccle>                     \[[@B68-pharmaceuticals-11-00057]\]

  COSMIC                                          Disease            Catalogue of somatic mutations in human cancer                                                                                                                                                                                                                                                                                                   <http://cancer.sanger.ac.uk/cosmic>                           \[[@B69-pharmaceuticals-11-00057]\]

  dbGAP                                           Disease            Catalogue of somatic mutations causing cancer                                                                                                                                                                                                                                                                                                    <http://www.ncbi.nlm.nih.gov/gap>                             \[[@B70-pharmaceuticals-11-00057]\]

  dbSNP                                           Disease            Database of single nucleotide polymorphisms                                                                                                                                                                                                                                                                                                      <https://www.ncbi.nlm.nih.gov/snp>                            \[[@B71-pharmaceuticals-11-00057]\]

  dbVar                                           Disease            Public archives for genomic structural variation                                                                                                                                                                                                                                                                                                 <https://www.ncbi.nlm.nih.gov/dbvar>                          \[[@B72-pharmaceuticals-11-00057]\]

  DisGeNET                                        Disease            Database on human disease-associated genes and variants                                                                                                                                                                                                                                                                                          <http://www.disgenet.org/>                                    \[[@B73-pharmaceuticals-11-00057]\]

  ENCODE                                          Disease            Database of comprehensive parts list of functional elements in human genome                                                                                                                                                                                                                                                                      <https://genome.ucsc.edu/ENCODE/>                             \[[@B20-pharmaceuticals-11-00057]\]

  Genomics Data Commons                           Disease            Harmonized Cancer Datasets with 40 cancer mutated gene projects, 22,147 Genes and 3 million mutations                                                                                                                                                                                                                                            <https://gdc.cancer.gov/>                                     \[[@B74-pharmaceuticals-11-00057]\]

  GEO                                             Disease            High throughput gene expression datasets                                                                                                                                                                                                                                                                                                         <http://www.ncbi.nlm.nih.gov/geo>                             \[[@B75-pharmaceuticals-11-00057]\]

  GTex                                            Disease            Catalog of genetic variations and their influence on gene expressions                                                                                                                                                                                                                                                                            <https://www.gtexportal.org/home/>                            \[[@B76-pharmaceuticals-11-00057]\]

  Human Proteome Map                              Disease            Interactive resource with massive peptide sequencing results                                                                                                                                                                                                                                                                                     <http://www.humanproteomemap.org/>                            \[[@B77-pharmaceuticals-11-00057]\]

  ICGC                                            Disease            Dataset with more than 17,000 cancer donors spanning 76 projects and 21 tumor sites                                                                                                                                                                                                                                                              <http://icgc.org/>                                            \[[@B78-pharmaceuticals-11-00057]\]

  IGSR                                            Disease            1000 genome project data usability and extension                                                                                                                                                                                                                                                                                                 <http://www.internationalgenome.org/>                         \[[@B79-pharmaceuticals-11-00057]\]

  Orphadata                                       Disease            Rare diseases, drugs and associated genes                                                                                                                                                                                                                                                                                                        <http://www.orphadata.org/cgi-bin/index.php/>                 \[[@B80-pharmaceuticals-11-00057]\]

  Roadmap Epigenomics                             Disease            Epigenomic maps for stem cells and primary ex vivo tissues selected to represent the normal counterparts of tissues and organ systems frequently involved in human disease                                                                                                                                                                       <http://www.roadmapepigenomics.org/>                          \[[@B81-pharmaceuticals-11-00057]\]

  STRING                                          Disease            Protein-Protein interaction, analysis, and networks                                                                                                                                                                                                                                                                                              <https://string-db.org/cgi/input.pl>                          \[[@B82-pharmaceuticals-11-00057]\]
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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###### 

Open innovation research resources.

  Name                                       Description                                                                                                                                                       URL
  ------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------
  Centers for Therapeutic Innovation (CTI)   Collaborative research platform for clinical applications and drug discovery \[[@B118-pharmaceuticals-11-00057]\]                                                 <https://www.pfizercti.com>
  CREEDS                                     Crowd-extracted expression of differential signatures \[[@B119-pharmaceuticals-11-00057]\]                                                                        <http://amp.pharm.mssm.edu/CREEDS>
  Grants4Leads                               Financial support for exploration of new approaches in infectious diseases \[[@B120-pharmaceuticals-11-00057]\]                                                   <https://www.grants4leads.com/>
  Kaggle                                     Data scientists and statisticians competition platform with few bioinformatics challenges \[[@B117-pharmaceuticals-11-00057],[@B121-pharmaceuticals-11-00057]\]   <http://www.kaggle.com/>
  Open Innovation Drug Discovery             Academic and Industry researchers open collaboration platform for drug discovery \[[@B122-pharmaceuticals-11-00057]\]                                             <https://openinnovation.lilly.com/dd/>
  Sage Bionetworks                           Bioinformatics and data science challenge platform building prognostic models for breast cancer \[[@B123-pharmaceuticals-11-00057]\]                              <http://sagebionetworks.org/>
  TopCoder                                   Machine learning engineers, programmers and data scientists challenge platform \[[@B116-pharmaceuticals-11-00057]\]                                               <http://www.topcoder.com>
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###### 

NIH-NCATS funded new therapeutic uses projects (2013--2018).

  Project/Study Title                                                                                                                           Year   NCATS Program              Condition
  --------------------------------------------------------------------------------------------------------------------------------------------- ------ -------------------------- -----------------------------------
  The Efficacy and Safety of a Selective Estrogen Receptor Beta Agonist (LY500307)                                                              2013   NIH-Industry Partnership   Schizophrenia
  Fyn Inhibition by AZD0530 for Alzheimer's Disease                                                                                             2013   NIH-Industry Partnership   Alzheimer's disease
  Medication Development of a Novel Therapeutic for Smoking Cessation                                                                           2013   NIH-Industry Partnership   Cigarette smoking
  A Novel Compound for Alcoholism Treatment: A Translational Strategy                                                                           2013   NIH-Industry Partnership   Alcoholism
  Partnering to Treat an Orphan Disease: Duchenne Muscular Dystrophy                                                                            2013   NIH-Industry Partnership   Duchenne muscular dystrophy
  Reuse of ZD4054 for Patients with Symptomatic Peripheral Artery Disease                                                                       2013   NIH-Industry Partnership   Peripheral artery disease
  Therapeutic Strategy for Lymphangioleiomyomatosis                                                                                             2013   NIH-Industry Partnership   Lymphangioleiomyomatosis
  Therapeutic Strategy to Slow Progression of Calcific Aortic Valve Stenosis                                                                    2013   NIH-Industry Partnership   Calcific aortic valve stenosis
  Translational Neuroscience Optimization of GlyT1 Inhibitor                                                                                    2013   NIH-Industry Partnership   Schizophrenia
  Anti-inflammatory Small Drug as Adjunctive Therapy to Improve Glucometabolic Variables in Obese, Insulin-Resistant Type 2 Diabetic Patients   2015   NIH-Industry Partnership   Insulin-resistant type 2 diabetes
  Evaluation of AZD9291 in Glioblastoma Patients with Activated EGFR                                                                            2015   NIH-Industry Partnership   Glioblastoma
  Evaluation of a Cathepsin S Inhibitor as a Potential Drug for Chagas Disease                                                                  2015   NIH-Industry Partnership   Chagas disease
  Wee1 and HDAC Inhibition in Relapsed/Refractory AML                                                                                           2015   NIH-Industry Partnership   Relapsed/refractory AML
  Anti-Virulence Drug Repurposing Using Structural Systems Pharmacology                                                                         2016   Bench-to-Clinic            Bacterial virulence
  CXCR2 Antagonism in the Immunometabolic Regulation of Type 2 Diabetes                                                                         2016   Bench-to-Clinic            Type 2 diabetes
  Drug Repositioning in Diabetic Nephropathy                                                                                                    2016   Bench-to-Clinic            Diabetic nephropathy
  Ketorolac and Related NSAIDs for Targeting Rho-Family GTPases in Ovarian Cancer                                                               2016   Bench-to-Clinic            Ovarian cancer
  Network-Driven Drug Repurposing Approaches to Treat Coronary Artery Disease                                                                   2016   Bench-to-Clinic            Coronary artery disease
  Pre-Clinical Evaluation of a Neutrophil Elastase Inhibitor for the Treatment of Inflammatory Bowel Disease                                    2016   Bench-to-Clinic            Inflammatory bowel disease
  Quantum Model Repurposing of Cethromycin for Liver Stage Malaria                                                                              2016   Bench-to-Clinic            Liver-stage malaria
  Repurposing Lesogaberan for the Treatment of Type 1 Diabetes                                                                                  2016   Bench-to-Clinic            Type 1 diabetes
  Repurposing Misoprostol for Clostridium Difficile Colitis as Identified by PheWAS                                                             2016   Bench-to-Clinic            Clostridium difficile colitis
  Repurposing Pyronaridine as a Treatment for the Ebola Virus                                                                                   2016   Bench-to-Clinic            Ebola virus
  Therapeutic Repurposing of Benserazide for Colon Cancer                                                                                       2016   Bench-to-Clinic            Colon cancer
  Computational Repurposing of Chemotherapies for Pulmonary Hypertension                                                                        2017   Bench-to-Clinic            Pulmonary hypertension
  Pre-Clinical Evaluation of Vorinostat in Alopecia Areata                                                                                      2017   Bench-to-Clinic            Alopecia areata
  Pre-Clinical Testing of a Novel Therapeutic for Nonalcoholic Steatohepatitis                                                                  2017   Bench-to-Clinic            Nonalcoholic steatohepatitis
  Repurposing Pyronaridine as a Treatment for Chagas Disease                                                                                    2017   Bench-to-Clinic            Chagas disease
  Single-Cell-Driven Drug Repositioning Approaches to Target Inflammation in Atherosclerosis                                                    2017   Bench-to-Clinic            Atherosclerosis
  Impact of SAR152954 on Prenatal Alcohol Exposure-Induced Neurobehavioral Deficits                                                             2017   Bench-to-Clinic            Neurobehavioral deficits
  An Endoplasmic Reticulum Calcium Stabilizer for the Treatment of Wolfram Syndrome                                                             2017   Bench-to-Clinic            Wolfram syndrome
  Utilization of Phenotypic Precision Medicine to Identify Optimal Drug Combinations for the Treatment of Hepatocellular Carcinoma              2017   Bench-to-Clinic            Hepatocellular carcinoma
  Targeting Glucose Metabolism for the Treatment of Hepatocellular Carcinoma                                                                    2017   Bench-to-Clinic            Hepatocellular carcinoma
  Application of a Repurposed FDA Approved Drug as a Local Osteogenic Agent                                                                     2017   Bench-to-Clinic            To induce local osteogenesis
  Repurposing Misoprostol to Prevent Recurrence of Clostridium Difficile Infection                                                              2018   Bench-to-Clinic            Recurrent Clostridium difficile
  AZD9668: A First in Class Disease Modifying Therapy to Treat Alpha-1 Antitrypsin Deficiency, a Genetically Linked Orphan Disease              2018   NIH-Industry Partnership   Alpha-1 antitrypsin deficiency
  AZD9668 and Neutrophil Elastase Inhibition to Prevent Graft-versus-Host Disease                                                               2018   NIH-Industry Partnership   Graft-versus-host disease
  Use of the Src Family Kinase Inhibitor Saracatinib in the Treatment of Pulmonary Fibrosis                                                     2018   NIH-Industry Partnership   Pulmonary fibrosis
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###### 

Web-tools and open source kits.

  Tool                    Description                                                                                                                                            URL                                                                     Ref
  ----------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------- --------------------------------------
  Clue                    Tools for perturbagens (small molecules or genes) query, L1000 cohorts, and gene expression heatmap visualization                                      <https://clue.io>                                                       \[[@B44-pharmaceuticals-11-00057]\]
  Clue Repurposing Tool   Interactive application to access approved and pre-clinical drug annotations                                                                           <https://clue.io/repurposing>                                           \[[@B137-pharmaceuticals-11-00057]\]
  COGENA                  Analysis, visualizing and clustering tool for gene expression profiles                                                                                 <https://github.com/zhilongjia/cogena>                                  \[[@B138-pharmaceuticals-11-00057]\]
  DeepChem                Deep learning toolkit for drug discovery and cheminformatics                                                                                           <https://deepchem.io/>                                                  \[[@B139-pharmaceuticals-11-00057]\]
  DR.PRODIS               Prediction of drug-protein interactions, side effects                                                                                                  <http://cssb.biology.gatech.edu/repurpose>                              \[[@B140-pharmaceuticals-11-00057]\]
  e-LEA3D                 Collection of tools related to computer-aided drug design                                                                                              <http://chemoinfo.ipmc.cnrs.fr/>                                        \[[@B141-pharmaceuticals-11-00057]\]
  Frog2                   Chemo-informatics toolkit for small compound 3D generation from 1D/2D input                                                                            <http://bioserv.rpbs.univ-paris-diderot.fr/services/Frog2/>             \[[@B142-pharmaceuticals-11-00057]\]
  GIFT                    Infer chemogenomic features from drug-target interactions.                                                                                             <http://bioinfo.au.tsinghua.edu.cn/software/GIFT/>                      \[[@B143-pharmaceuticals-11-00057]\]
  GoPredict               Drug target prioritization tool for breast and ovarian cancer                                                                                          <http://csblcanges.fimm.fi/GOPredict/>                                  \[[@B144-pharmaceuticals-11-00057]\]
  JOELib/JOELib2          Toolkit to interconvert chemical file formats, descriptor calculation classes, and SMARTS substructure search                                          <http://www.ra.cs.uni-tuebingen.de/software/joelib/introduction.html>   \[[@B145-pharmaceuticals-11-00057]\]
  ksRepo                  Drug repositioning tool that utilizes gene expression drug datasets from different platforms                                                           <https://github.com/adam-sam-brown/ksRepo>                              \[[@B101-pharmaceuticals-11-00057]\]
  L1000CDS                L1000 dataset based gene expression signature search engine                                                                                            <http://amp.pharm.mssm.edu/L1000CDS2/#/index>                           \[[@B146-pharmaceuticals-11-00057]\]
  MANTRA                  Prediction and analysis of mechanism of action of drugs for drug repositioning                                                                         <http://mantra.tigem.it/>                                               \[[@B147-pharmaceuticals-11-00057]\]
  NFFinder                Tool to discover multiple drugs with similar drugs based on up/down regulated genes                                                                    <http://nffinder.cnb.csic.es/>                                          \[[@B102-pharmaceuticals-11-00057]\]
  Open babel              Open source chemistry toolbox                                                                                                                          <http://openbabel.org/wiki/Main_Page>                                   \[[@B148-pharmaceuticals-11-00057]\]
  Open PHACTS             European funded initiative to bring together industry and academic partners for semantic integration of pharmacological data using an RDF data model   <http://www.openphacts.org>                                             \[[@B149-pharmaceuticals-11-00057]\]
